project id: TCGA-BLCA; case submitter id: TCGA-XF-AAMY; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 2.01; rna integrity number: 8.9; age at index: 78; days to birth: -28509; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1928; age at diagnosis: 28509; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T3b; ajcc staging system edition: 5th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 3011.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8130/3; primary diagnosis: Papillary transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: Not Reported; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2006; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 2758; days to sample procurement: 0; initial weight: 1090.0; portion submitter id: TCGA-XF-AAMY-01A-11; percent lymphocyte infiltration: 4.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 3.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0;